Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1979 Feb;76(2):958–961. doi: 10.1073/pnas.76.2.958

Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.

O D Ratnoff, H Saito
PMCID: PMC383106  PMID: 284420

Abstract

To investigate the earliest steps of the intrinsic clotting pathway, Hageman factor (Factor XII) was exposed to Sephadex gels to which ellagic acid had been adsorbed; Hageman factor was then separated from the gels and studied in the fluid phase. Sephadex-ellagic acid-exposed Hageman factor, whether purified or in plasma, activated plasma thromboplastin antecedent, but only when high molecular weight kininogen was presnet. In the absence of plasma prekallikrein, maximal activation of plasma thromboplastin antecedent was slightly delayed in plasma, a delay not observed with similarly treated purified Hageman factor. Thus, high molecular weight kininogen was needed for expression of Hageman factor's clot-promoting properties and plasma prekallikrein played a minor role in the interaction of ellagic acid-treated Hageman factor and plasma thromboplastin antecedent.

Full text

PDF
959

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chan J. Y., Habal F. M., Burrowes C. E., Movat H. Z. Interaction between factor XII (Hageman factor), high molecular weight kininogen and prekallikrein. Thromb Res. 1976 Nov;9(5):423–433. doi: 10.1016/0049-3848(76)90198-5. [DOI] [PubMed] [Google Scholar]
  2. Colman R. W., Bagdasarian A., Talamo R. C., Scott C. F., Seavey M., Guimaraes J. A., Pierce J. V., Kaplan A. P. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest. 1975 Dec;56(6):1650–1662. doi: 10.1172/JCI108247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cuatrecasas P., Wilchek M., Anfinsen C. B. Selective enzyme purification by affinity chromatography. Proc Natl Acad Sci U S A. 1968 Oct;61(2):636–643. doi: 10.1073/pnas.61.2.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  5. Donaldson V. H., Glueck H. I., Miller M. A., Movat H. Z., Habal F. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med. 1976 Feb;87(2):327–337. [PubMed] [Google Scholar]
  6. Donaldson V. H., Ratnoff O. D. Hageman factor: alterations in physical properties during activation. Science. 1965 Nov 5;150(3697):754–756. doi: 10.1126/science.150.3697.754. [DOI] [PubMed] [Google Scholar]
  7. Fair B. D., Saito H., Ratnoff O. D., Rippon W. B. Detection by fluorescence of structural changes accompanying the activation of Hageman factor (factor XII). Proc Soc Exp Biol Med. 1977 Jun;155(2):199–202. doi: 10.3181/00379727-155-39773. [DOI] [PubMed] [Google Scholar]
  8. Fujikawa K., Kurachi K., Davie E. W. Characterization of bovine factor XIIa (activated Hageman factor). Biochemistry. 1977 Sep 20;16(19):4182–4188. doi: 10.1021/bi00638a008. [DOI] [PubMed] [Google Scholar]
  9. Griffin J. H., Cochrane C. G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A. 1976 Aug;73(8):2554–2558. doi: 10.1073/pnas.73.8.2554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hathaway W. E., Belhasen L. P., Hathaway H. S. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood. 1965 Nov;26(5):521–532. [PubMed] [Google Scholar]
  11. Kaplan A. P., Austen K. F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696–712. doi: 10.1084/jem.133.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McMillin C. R., Saito H., Ratnoff O. D., Walton A. G. The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J Clin Invest. 1974 Dec;54(6):1312–1322. doi: 10.1172/JCI107877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Meier H. L., Pierce J. V., Colman R. W., Kaplan A. P. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest. 1977 Jul;60(1):18–31. doi: 10.1172/JCI108754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. RATNOFF O. D., CRUM J. D. ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID. J Lab Clin Med. 1964 Mar;63:359–377. [PubMed] [Google Scholar]
  15. Ratnoff O. D. Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI). J Lab Clin Med. 1972 Nov;80(5):704–710. [PubMed] [Google Scholar]
  16. Revak S. D., Cochrane C. G., Griffin J. H. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest. 1977 Jun;59(6):1167–1175. doi: 10.1172/JCI108741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saito H., Goldsmith G. H., Jr Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay. Blood. 1977 Sep;50(3):377–385. [PubMed] [Google Scholar]
  18. Saito H. Purification of high molecular weight kininogen and the role of this agent in blood coagulation. J Clin Invest. 1977 Sep;60(3):584–594. doi: 10.1172/JCI108810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Saito H., Ratnoff O. D., Donaldson V. H. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circ Res. 1974 May;34(5):641–651. doi: 10.1161/01.res.34.5.641. [DOI] [PubMed] [Google Scholar]
  20. Saito H., Ratnoff O. D., Donaldson V. H., Haney G., Pensky J. Inhibition of the adsorption of Hagemen factor (Factor XII) to glass by normal human plasma. J Lab Clin Med. 1974 Jul;84(1):62–73. [PubMed] [Google Scholar]
  21. Saito H., Ratnoff O. D. Inhibition of normal clotting and Fletcher factor activity by rabbit anti-kallikrein antiserum. Nature. 1974 Apr 12;248(449):597–598. doi: 10.1038/248597a0. [DOI] [PubMed] [Google Scholar]
  22. Saito H., Ratnoff O. D., Waldmann R., Abraham J. P. Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil). J Clin Invest. 1975 May;55(5):1082–1089. doi: 10.1172/JCI108009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schiffman S., Lee P. Partial purification and characterization of contact activation cofactor. J Clin Invest. 1975 Nov;56(5):1082–1092. doi: 10.1172/JCI108182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schiffman S., Pecci R., Lee P. Contact activation of factor XI: evidence that the primary role of contact activation cofactor (CAC) is to facilitate the activation of factor XII. Thromb Res. 1977 Feb;10(2):319–323. doi: 10.1016/0049-3848(77)90014-7. [DOI] [PubMed] [Google Scholar]
  25. Webster M. E., Guimaraes J. A., Kaplan A. P., Colman R. W., Pierce J. V. Activation of surface-bound Hageman factor: pre-eminent role of high molecular weight kininogen and evidence for a new factor. Adv Exp Med Biol. 1976;70(00):285–299. doi: 10.1007/978-1-4684-3267-1_35. [DOI] [PubMed] [Google Scholar]
  26. Weiss A. S., Gallin J. I., Kaplan A. P. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest. 1974 Feb;53(2):622–633. doi: 10.1172/JCI107597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wuepper K. D., Miller D. R., Lacombe M. J. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest. 1975 Dec;56(6):1663–1672. doi: 10.1172/JCI108248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES